Sarepta Therapeutics, Inc. Investors: Company Investigated by the Portnoy Law Firm

Investors can contact the law firm at no cost to learn more about recovering their losses

/EIN News/ -- ​LOS ANGELES, March 18, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Sarepta Therapeutics, Inc. (“Sarepta” or “the Company”) (NASDAQ: SRPT) investors that the firm has initiated an investigation into possible securities fraud and may file a class action on behalf of investors. Sarepta investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq.

Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: info@portnoylaw.com, to discuss their legal rights, or click here to join the case. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.

Sarepta Therapeutics' stock plunged by as much as 27% on March 18, 2025, after the company announced that a patient had died following treatment with its gene therapy, Elevidys, for Duchenne muscular dystrophy (DMD).

RBC Capital Markets noted that this news could make doctors more cautious when prescribing the medication to new patients.

According to Sarepta, the patient suffered from acute liver failure.

Please visit our website to review more information and submit your transaction information.

The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.

Lesley F. Portnoy, Esq.
Admitted CA, NY and TX Bars
lesley@portnoylaw.com
310-692-8883
www.portnoylaw.com

Attorney Advertising